Session Track · IDC 2027

Yellow Nail Syndrome at IDC 2027

Part of the IDC 2027 scientific program · NH Villa Carpegna, Rome, Italy · June 21–23, 2027

About the Yellow Nail Syndrome Session

Yellow Nail Syndrome (YNS) is a rare medical disorder that primarily affects the nails of the fingers and toes. It is characterized by yellow discoloration and thickening of the nails of the digits due to accumulation of endothelial cells, which results in abnormal hardening and increased curvature. The exact cause of YNS is unknown, but it is thought to be due to an underlying lymphatic disorder, such as lymphatic malformation or lymphocytic leukocytosis. It is believed that the excessive accumulation of endothelial cells in the nail bed leads to the typical yellowish discoloration of the nail plate. Patients with YNS typically experience pain and discomfort due to the abnormal thickening and curling of their nails. Additionally, those affected by the condition may experience peels and ridging of the nail from the presence of the hardening cells. In some cases, nails may become so thick they impede one’s ability to wear footwear normally. There is no universal treatment for YNS, but some common treatments focus on softening the nails and reducing their thickness. A dermatologist may recommend medications such as topical antifungal agents, intralesional triamcinolone, retinoids, and oral steroids. Additionally, light curettage of the nails and laser ablation can be used to remove the thickened cells. Although YNS is rare, people of any age or gender can be affected. If you or a family member is experiencing yellow discoloration and thickening of the nails, seeing a dermatologist for evaluation may be beneficial. Even though there is no known cure, there are treatments that can provide relief and improve nail aesthetics.

Featured Speakers — Yellow Nail Syndrome 2027

Speaker lineup for this track will be announced soon.

Browse all speakers →

Recent Research Presented at Yellow Nail Syndrome Sessions

Selected abstracts from this track will be published here.

Related Scientific Sessions at IDC 2027

Why Attend the Yellow Nail Syndrome Conference 2027

Present Your Research

Oral and poster slots for original Yellow Nail Syndrome work, reviewed by the scientific committee.

Network Globally

Meet researchers, clinicians, and industry leaders from around the world across three days.

Publish & Get Indexed

Accepted abstracts appear in the indexed conference proceedings with a citable DOI.

Learn from Keynotes

Plenary lectures from leading voices shaping Yellow Nail Syndrome research and practice.

Hybrid Flexibility

Attend in person in Rome or join virtually — same program, same certificate.

Join IDC 2027 for the Yellow Nail Syndrome track

Oral and poster slots for your work — in person in Rome or online. Not presenting? Attend as a delegate to learn from the field.

Yellow Nail Syndrome Conference 2027 — FAQs

What is the Yellow Nail Syndrome track at IDC 2027?

The Yellow Nail Syndrome track is a dedicated stream within IDC 2027 covering the latest research, clinical innovation, and best practice in Yellow Nail Syndrome. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.

Who should attend the Yellow Nail Syndrome sessions?

Researchers, clinicians, educators, doctoral students, and industry leaders with an interest in Yellow Nail Syndrome are all welcome — whether presenting or attending.

Can I present my research in the Yellow Nail Syndrome track?

Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.

Is virtual attendance available for Yellow Nail Syndrome sessions?

Yes. IDC 2027 is a hybrid conference — attend the Yellow Nail Syndrome track in person in Rome or join live online, with on-demand access afterward.

Join the IDC 2027 delegation

Rome · June 21–23, 2027 · Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.